Marker Therapeutics gains on U.S. FDA grant for blood cancer therapy trial

Marker Therapeutics

13/09/2022 16:03

** Shares of Marker Therapeutics Inc  MRKR.O  rise 4% to
$0.47 in morning trade
    ** Co says it has received $2 mln FDA grant for mid-stage
trial of its lead product candidate, MT-401, for treating
patients with post-transplant acute myeloid leukemia (AML)
 urn:newsml:reuters.com:*:nGNXbVmjss
    ** MT-401 already has "orphan drug" tag from regulator for
treatment of AML following type of stem cell transplant 
    ** Orphan drug status is given by FDA to drugs which treat
rare conditions and are protected through a series of government
incentives once on market
    ** AML is a type of cancer in which the bone marrow makes a
large number of abnormal blood cells
    ** Including session's gain, stock down ~50% YTD

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))